Aunque queremos hablar principalmente de los medicamentos GLP-1, es importante conocer los del tipo agonista dual: los GLP o GIP
There are currently no published clinical trials evaluating the safety or efficacy of compounded GLP-1 ODTs
HIF-1 is activated due to blockade of its degradation pathway mediated by low oxygen levels, thereby increasing the expression of target genes, including those encoding glycolytic enzymes and glucose transporters, and increasing lactate secretion 67
This includes potential effects on autophagy and protection against neurotoxicity
Performance declines (slower recovery, reduced training capacity, higher injury risk)
When stopping Semaglutide abruptly, some patients may experience mild to moderate weight gain